Venn Life Sciences Holdings PLC Partnership Announcement
18 Enero 2019 - 01:00AM
RNS Non-Regulatory
TIDMVENN
Venn Life Sciences Holdings PLC
18 January 2019
18.01.2019
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Partnership Announcement
Venn Life Sciences ("Venn") an Integrated Drug Development
Partner offering a combination of drug development expertise and
clinical trial design and management to pharmaceutical,
biotechnology and medical device organisations announces its
partnership with Carrick Therapeutics Ltd ("Carrick
Therapeutics").
Venn Life Sciences announce partnership
Carrick Therapeutics is building an innovative portfolio of
first-in-class treatments that target multiple mechanisms of the
most aggressive forms of cancer and are optimised to a patient's
individual tumour through identification of predictive biomarkers.
Carrick Therapeutics has built a network of partners and
collaborators to progress its technology portfolio and Venn is
delighted to join this network as a provider of Early Development
and Clinical Research capabilities.
About Carrick Therapeutics:
Carrick Therapeutics has a clear vision for cancer patients: to
target the molecular pathways that drive the most aggressive and
resistant forms of cancer in order to have a major impact on the
lives of patients. Whilst other companies bank on a single compound
or biological mechanism, Carrick Therapeutics is building an
innovative portfolio of first-in-class treatments that are advanced
through understanding the mechanisms that cause cancer and
resistance, allied with cutting-edge technologies to identify
therapeutics and those who would most benefit from them.
Commenting on this development, Tony Richardson CEO of Venn Life
Sciences stated;
In so many respects Carrick Therapeutics represents the model
client for Venn. Highly innovative with a portfolio approach
focusing on their core IP while working on an outsource basis with
a well-developed network of support partners. At Venn we have built
a suite of capabilities designed to address all of the development
requirements of this model and are delighted to partner with
Carrick in the development of their first in class treatments."
Commenting on this development, Elaine Sullivan CEO of Carrick
Therapeutics stated;
By linking a network of clinicians and scientists in
internationally leading research institutes and hospitals, we will
use our multi-asset portfolio to drive the development of these
ground-breaking cancer therapies from laboratory to clinic.
Together with our academic and biotech partners, we are looking to
detect predictive biomarkers in each of our projects to enable us
to identify those who would benefit most from our therapies. These
targeted treatments will bring a higher quality of life to cancer
patients around the world. We are partnering with Venn to provide
development and clinical capabilities and they are a welcome
addition to our network.
Enquiries:
Venn Life Sciences Holdings Plc Tel: +353 1 5499 341
Tony Richardson, Chief Executive Officer
Cenkos (Nominated Advisor and Co-Broker) Tel: +44 (0)20 7397
8900
Mark Connelly / Steve Cox (Corporate Finance)
Davy (ESM Adviser and Co-Broker) Tel: +353 (0)1 679 6363
Fergal Meegan / Matthew de Vere White (Corporate Finance)
About Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner
offering a unique combination of drug development expertise and
clinical trial design and management to pharmaceutical,
biotechnology and medical device organisations. Venn have dedicated
operations in France, Germany, the Netherlands, the UK, Ireland
with partners across Europe and the US.
Further information in relation to Venn Life Sciences
www.vennlifesciences.com
Venn life Science: getintouch@vennlife.com
Carrick Therapeutic: elaine.sullivan@carricktherapeutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKODBOBKDCDD
(END) Dow Jones Newswires
January 18, 2019 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024